JP2022173554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022173554A5 JP2022173554A5 JP2022160357A JP2022160357A JP2022173554A5 JP 2022173554 A5 JP2022173554 A5 JP 2022173554A5 JP 2022160357 A JP2022160357 A JP 2022160357A JP 2022160357 A JP2022160357 A JP 2022160357A JP 2022173554 A5 JP2022173554 A5 JP 2022173554A5
- Authority
- JP
- Japan
- Prior art keywords
- strand
- nucleic acid
- positions
- modified
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 125000003729 nucleotide group Chemical group 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 24
- 230000004048 modification Effects 0.000 claims 11
- 238000012986 modification Methods 0.000 claims 11
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- -1 alkylene ether Chemical group 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024121088A JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165129 | 2017-04-05 | ||
| EP17165129.2 | 2017-04-05 | ||
| GBGB1707203.4A GB201707203D0 (en) | 2017-05-05 | 2017-05-05 | Modified positions |
| GB1707203.4 | 2017-05-05 | ||
| GBGB1708397.3A GB201708397D0 (en) | 2017-05-25 | 2017-05-25 | Modified positions |
| GB1708397.3 | 2017-05-25 | ||
| EP17201352 | 2017-11-13 | ||
| EP17201352.6 | 2017-11-13 | ||
| JP2020504436A JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
| PCT/EP2018/058766 WO2018185241A1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504436A Division JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024121088A Division JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022173554A JP2022173554A (ja) | 2022-11-18 |
| JP2022173554A5 true JP2022173554A5 (https=) | 2022-12-06 |
| JP7583005B2 JP7583005B2 (ja) | 2024-11-13 |
Family
ID=61899311
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504436A Active JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
| JP2022160357A Active JP7583005B2 (ja) | 2017-04-05 | 2022-10-04 | 産物及び組成物 |
| JP2024121088A Active JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504436A Active JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024121088A Active JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11015198B2 (https=) |
| EP (2) | EP3607069B1 (https=) |
| JP (3) | JP7155239B2 (https=) |
| CN (1) | CN110520531A (https=) |
| AU (1) | AU2018247925B2 (https=) |
| DK (1) | DK3607069T3 (https=) |
| ES (1) | ES2932831T3 (https=) |
| FI (1) | FI3607069T3 (https=) |
| HR (1) | HRP20221400T1 (https=) |
| HU (1) | HUE061247T2 (https=) |
| IL (2) | IL321221A (https=) |
| LT (1) | LT3607069T (https=) |
| PL (1) | PL3607069T3 (https=) |
| RS (1) | RS63836B1 (https=) |
| SI (1) | SI3607069T1 (https=) |
| WO (1) | WO2018185241A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| EP3483269A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| EP4029942A1 (en) | 2017-04-05 | 2022-07-20 | Silence Therapeutics GmbH | Products and compositions |
| WO2018185240A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| JP7155239B2 (ja) | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| CA3083968C (en) * | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| EP3598995A1 (en) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
| JP7627042B2 (ja) * | 2018-08-23 | 2025-02-05 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| BR112021009213A2 (pt) | 2018-11-13 | 2021-08-10 | Silence Therapeutics Gmbh | ácidos nucleicos para inibição da expressão de lpa em uma célula |
| KR20210116509A (ko) * | 2019-01-16 | 2021-09-27 | 젠자임 코포레이션 | Serpinc1 irna 조성물 및 그의 이용 방법 |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| CA3135402A1 (en) * | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| MX2022001710A (es) | 2019-08-09 | 2022-05-10 | Univ Massachusetts | Oligonucleótidos modificados químicamente dirigidos a los snp. |
| JP2022545118A (ja) * | 2019-08-23 | 2022-10-25 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| EP4048801A4 (en) * | 2019-10-24 | 2023-11-22 | Genevant Sciences Gmbh | Conjugates and methods for treating acromegaly |
| KR20220163960A (ko) | 2020-03-06 | 2022-12-12 | 알리고스 테라퓨틱스 인코포레이티드 | 변경된 짧은 개재성 핵산(siNA) 분자 및 이의 용도 |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| JP2023549011A (ja) | 2020-09-15 | 2023-11-22 | ヴァーヴ・セラピューティクス，インコーポレーテッド | 遺伝子編集のための脂質製剤 |
| AU2021373262A1 (en) | 2020-11-04 | 2023-06-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of pros1 in a cell |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| WO2022204430A1 (en) * | 2021-03-24 | 2022-09-29 | Atalanta Therapeutics, Inc. | Double-stranded sirna having patterned chemical modifications |
| AU2022299169A1 (en) | 2021-06-23 | 2024-02-08 | Beth Israel Deaconess Medical Center, Inc. | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| EP4493570A2 (en) | 2022-03-16 | 2025-01-22 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| KR20240163743A (ko) | 2022-03-28 | 2024-11-19 | 엠피리코 인크. | 변형된 올리고뉴클레오티드 |
| EP4687983A1 (en) | 2023-03-27 | 2026-02-11 | Silence Therapeutics GmbH | Compounds and compositions for use in stem cell transplantation |
| WO2024245151A1 (zh) * | 2023-05-26 | 2024-12-05 | 维亚臻生物技术（苏州）有限公司 | 一种用于代谢疾病的双链核苷酸化合物及其应用 |
| AU2024321098A1 (en) * | 2023-08-09 | 2026-03-19 | Beijing Foyou Pharma Co., Ltd | Sirna for inhibiting dgat2 gene expression, sirna conjugate or prodrug and pharmaceutical composition thereof, and use thereof |
| TW202602463A (zh) | 2024-03-22 | 2026-01-16 | 日商武田藥品工業股份有限公司 | 用於抑制細胞色素ｐ４５０家族７次家族ａ成員１（ｃｙｐ７ａ１）表現之組成物及方法 |
| CN118460651B (zh) * | 2024-07-10 | 2025-03-18 | 凯莱英医药集团（天津）股份有限公司 | 制备Cemdisiran的方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| KR20080036650A (ko) | 2005-08-17 | 2008-04-28 | 시르나 쎄러퓨틱스 인코퍼레이티드 | Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자 |
| US20090306178A1 (en) * | 2006-03-27 | 2009-12-10 | Balkrishen Bhat | Conjugated double strand compositions for use in gene modulation |
| US20110046206A1 (en) * | 2007-06-22 | 2011-02-24 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| MX2010008394A (es) | 2008-01-31 | 2010-11-12 | Alnylam Pharmaceuticals Inc | Metodos optimizados para administracion de arndc focalizando el gen pcsk9. |
| US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
| EP2342616A2 (en) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| US9493774B2 (en) * | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| CA2812046A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| WO2012094115A1 (en) | 2010-12-17 | 2012-07-12 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of flt3 genes |
| CA2834610A1 (en) * | 2011-06-06 | 2012-12-13 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression |
| HRP20181564T1 (hr) | 2011-06-30 | 2018-11-30 | Arrowhead Pharmaceuticals, Inc. | Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b |
| EP2780454A2 (en) * | 2011-11-18 | 2014-09-24 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| HUE048622T2 (hu) * | 2011-11-18 | 2020-08-28 | Alnylam Pharmaceuticals Inc | RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| US10125369B2 (en) * | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
| DK2991656T3 (da) * | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| KR102486617B1 (ko) * | 2013-05-22 | 2023-01-12 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| JP6702862B2 (ja) | 2013-07-11 | 2020-06-03 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法 |
| WO2015188194A1 (en) | 2014-06-06 | 2015-12-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JP2018509913A (ja) | 2015-03-17 | 2018-04-12 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法 |
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| SMT202000454T1 (it) | 2015-04-03 | 2020-11-10 | Univ Massachusetts | Cmposti oligonucleotidici per bersagliare l'mrn della huntingtina |
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| US10633653B2 (en) * | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) * | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| WO2017214112A1 (en) | 2016-06-06 | 2017-12-14 | Arrowhead Pharmaceuticals, Inc. | 5'-cyclo-phosphonate modified nucleotides |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| BR112019014282A2 (pt) | 2017-01-10 | 2020-03-03 | Arrowhead Pharmaceuticals, Inc. | Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso |
| AU2018213379A1 (en) | 2017-01-30 | 2019-07-18 | Arrowhead Pharmaceuticals Inc. | Compositions and methods for inhibition of factor XII gene expression |
| WO2018185240A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| JP7155239B2 (ja) * | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| MX2020001912A (es) | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| MX2020004897A (es) * | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| CA3083968C (en) | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| BR112021009213A2 (pt) * | 2018-11-13 | 2021-08-10 | Silence Therapeutics Gmbh | ácidos nucleicos para inibição da expressão de lpa em uma célula |
-
2018
- 2018-04-05 JP JP2020504436A patent/JP7155239B2/ja active Active
- 2018-04-05 FI FIEP18715706.0T patent/FI3607069T3/fi active
- 2018-04-05 RS RS20221162A patent/RS63836B1/sr unknown
- 2018-04-05 IL IL321221A patent/IL321221A/en unknown
- 2018-04-05 EP EP18715706.0A patent/EP3607069B1/en active Active
- 2018-04-05 SI SI201830836T patent/SI3607069T1/sl unknown
- 2018-04-05 ES ES18715706T patent/ES2932831T3/es active Active
- 2018-04-05 AU AU2018247925A patent/AU2018247925B2/en active Active
- 2018-04-05 HU HUE18715706A patent/HUE061247T2/hu unknown
- 2018-04-05 CN CN201880021538.7A patent/CN110520531A/zh active Pending
- 2018-04-05 US US16/497,000 patent/US11015198B2/en active Active
- 2018-04-05 DK DK18715706.0T patent/DK3607069T3/da active
- 2018-04-05 HR HRP20221400TT patent/HRP20221400T1/hr unknown
- 2018-04-05 WO PCT/EP2018/058766 patent/WO2018185241A1/en not_active Ceased
- 2018-04-05 IL IL268828A patent/IL268828B2/en unknown
- 2018-04-05 EP EP22202294.9A patent/EP4219713A3/en active Pending
- 2018-04-05 PL PL18715706.0T patent/PL3607069T3/pl unknown
- 2018-04-05 LT LTEPPCT/EP2018/058766T patent/LT3607069T/lt unknown
-
2021
- 2021-03-31 US US17/219,265 patent/US12084656B2/en active Active
-
2022
- 2022-10-04 JP JP2022160357A patent/JP7583005B2/ja active Active
-
2024
- 2024-07-26 JP JP2024121088A patent/JP7823127B2/ja active Active
- 2024-08-07 US US18/797,143 patent/US20250043288A1/en active Pending